{"name":"Celcuity","slug":"celcuity","ticker":"CELC","exchange":"NASDAQ","domain":"celcuity.com","description":"Celcuity is a precision oncology company focused on developing targeted therapies for cancer patients. The company's lead product is its proprietary diagnostic test, which helps identify patients who are most likely to benefit from specific targeted therapies. Celcuity's therapeutic focus is on precision oncology, with a goal of improving patient outcomes and reducing healthcare costs. The company is positioned to capitalize on the growing demand for targeted therapies in the oncology market.","hq":"Minneapolis, MN","founded":0,"employees":"","ceo":"Brian Sullivan","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$850M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":144995000,"netIncome":-177042000,"cash":165703000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Celcuity Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Celcuity reported fourth quarter and full year 2023 financial results, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Celcuity Announces Collaboration with Leading Cancer Research Institution","summary":"Celcuity announced a collaboration with a leading cancer research institution to develop new targeted therapies for cancer patients.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"pipeline","source":"simplywall.st","summary":"Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending - simplywall.st","headline":"Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE44ZDE5aFZ4VG02N01wSU1raWpBaUY4bHlnRTFPQnkyQkNXWEtES1pVRlVUal95azZaYWg4NUpJOHdYVVZTeG1sSnNQQUxOR2pmd0E?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance Australia","summary":"Celcuity Inc. (CELC) stock price, news, quote and history - Yahoo Finance Australia","headline":"Celcuity Inc. (CELC) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"pipeline","source":"simplywall.st","summary":"Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run? - simplywall.st","headline":"Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"simplywall.st","summary":"Did Gedatolisib’s Priority Review and Commercial Build-Out Just Shift Celcuity's (CELC) Investment Narrative? - simplywall.st","headline":"Did Gedatolisib’s Priority Review and Commercial Build-Out Just Shift Celcuity's (CELC) Investment Narrative?","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPd3Q0SEI5dENwVzA0OVM5MmZwSER0SUFPcnNWQl9QYzMyMHJDdXNPUGtWbWVUTUt3Y2dBc0kzN2F1T2FNaGJneFc0U1Y0NHJoU2d2RzJaMmtqMnBWX2U3MWF5YzNnWkMyVE42am51UUswZGpUak5rT2ZVM0Rpbi15anlMdmVra2RISDY2TTdMeDdRMGtVRkp4RkxtVm1ZRkVvaEFGRjZzelpDZHpsRlRN?oc=5","date":"2025-12-24","type":"pipeline","source":"Seeking Alpha","summary":"Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC) - Seeking Alpha","headline":"Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxORF8wQ290YWFId0s0UUQ0c2FQUEpVNU5FZmdRT1NKNGw1X05OMDFWemZuc3pNWTByMnRGU0JDUWtxOGNCYkRiNHZOZi04ekt4WnFJSV9WanZwOWg2YUhNVFRidm5sRVVFQlhmZm1sdDRtWTI3Q1V0Y0Z0cnpRWGZJQnZSclBpTmJIeHl3Y1B5V0RiOThqVzUxNzJxZGdzR0lyUjlCVHFuZDNUNHRYSC0zQXhJNU1MeUx3?oc=5","date":"2025-11-23","type":"pipeline","source":"Finviz","summary":"Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View - Finviz","headline":"Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9oblBjMk91NG1GbnpzY2sxMjRmRC1qYlZ1WU1qN1ltRmcwOWxEVDE5UEphckl0TDhkWEJkVjdRdk5WMGlYc2xOWjk2ZDlBOVFRc0Y2YXB5SUo?oc=5","date":"2025-11-21","type":"regulatory","source":"webull.com","summary":"Celcuity (CELC) Is Up 9.3% After FDA NDA Submission for Gedatolisib in Breast Cancer Therapy - Has The Bull Case Changed? - webull.com","headline":"Celcuity (CELC) Is Up 9.3% After FDA NDA Submission for Gedatolisib in Breast Cancer Therapy - Has The Bull Case Changed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPa2MzZkNmZXpGR3lhd1c3SWFzTndjODBvWUpCVGNBRUg1RDJ5dXExeDhwbGMwOFJ1Smh0ZS1RZ3pGWGN3RVNQVUJKSlpvZ2hzbF9kdTJZTzI3a1ltdHhpbUFBN1YtR3VULXlTemZldk5VUWJfbTcyOFZ4UlRoM3RvanZkOXZRUzNxVlBtU1NSY24?oc=5","date":"2025-10-20","type":"pipeline","source":"Investor's Business Daily","summary":"Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results - Investor's Business Daily","headline":"Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQbzNzSGRjN0hlQzZKVUg1NmxGbnY3ejh3dzBzUVVuOVMtRlRLV0Ffand1QXV2a1R6REo5SUplbU9heGhwX0ZvZDdhRUNyZ1NkYlQ0REsyOV9DLTVJQVE5TTlFMDhOUTFERmdDZzNucndVUXJYRTNhUnlSUFV0dHJaOEJjakZKcWhHU1d1azEwUGx3M0JsSk5jbV96QS12eDF6?oc=5","date":"2025-07-29","type":"pipeline","source":"Forbes","summary":"Celcuity: What’s Happening With CELC Stock? - Forbes","headline":"Celcuity: What’s Happening With CELC Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ25lNzJSVWs0RnM0dmVJTlpDTzBqNFZtV1k3aHN1dnplNU80TDQ2S0RESmdhems5ek52Y3dDNmpXTHl6RUhyaVdQbEZhUjhUS2NHRzlWUElSX1pjcDVBVy13bVFUajl4d1NqT25Ecm9XUVBJV2ozNmVsaHVaeGQ3bTBwdlBJS1JtTk5saUR3?oc=5","date":"2025-07-28","type":"trial","source":"The Pharma Letter","summary":"Celcuity rockets on new gedatolisib data - The Pharma Letter","headline":"Celcuity rockets on new gedatolisib data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPbUJvb0hUUVI0MmZCc3p5SmNzajNYWlR5RzU5Y1FRbnJ2MEpsMjR1OUdyX0hEakNJVGFpWUtBQUxZWW5RZzFtS2I4NW1TZ2NvRklVU2d5YmZMYXhWT2JHSU5zelZ4aWFnRGZqQkN3X0NGbHQ5eTd4YkhCY2NvQ1d5SFN4bU9heTdaWjF4UHRZR1pfWEtLeHpXUDdjNlpmUmFuRjdhTndnMEVBeHhmUDlncElQSmVpSUhjR29oYmg1dEtfTDMwYnNZeFJMc0dTMGJLVXI5MU84aG1RYlE?oc=5","date":"2025-07-28","type":"pipeline","source":"Stocktwits","summary":"This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why - Stocktwits","headline":"This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9XS0g4TnpSZ1MzbDV1R19zSlR6RnlEWGI2anE3TXpsTVBnbVlVQmJuTE9EOHBud1EyTy01NExQQmJUc00tbEwzNTVTMHBZS3Ro?oc=5","date":"2024-03-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Foundation Medicine","Invitae","Guardant Health"],"therapeuticFocus":["Precision Oncology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":144995000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-177042000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":165703000,"cashHistory":[],"totalAssets":466558000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}